Atossa Therapeutics Inc
ATOS
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.31M
Close$
$4.80
174.1% upside
Current Fair Value
174.1% upsideUndervalued by 174.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $17.31 Million |
|---|---|
| Enterprise Value | $-14,409,166.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.04 |
| Beta | 1.15 |
| Outstanding Shares | 8,622,289 |
Return
| Return on Equity | -123.47% |
|---|---|
| Return on Assets | -99.20% |
| Return on Invested Capital | -93.65% |
Valuation & Multiples
| P/E Ratio | -0.46 |
|---|---|
| PEG | -1.08 |
| Price to Sales | - |
| Price to Book Ratio | 0.58 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.5 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.71
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-1.04
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 55.66% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 55,000▼ 21.76% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 14.38%▼ 2.61% |
|---|---|
| Total Invested | $6.52M▼ 49.64% |
| Investors Holding | 34▼ 33.00% |
ESG Score
No data
About Atossa Therapeutics Inc
CEO: Steven Quay Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.